|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2006-10-4
|
|
pubmed:abstractText |
Evidence that rofecoxib increases the risk of myocardial infarction has led to scrutiny of other nonsteroidal anti-inflammatory drugs (NSAIDs). Regulatory agencies have provided variable advice regarding the cardiovascular risks with older nonselective NSAIDs.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1538-3598
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
4
|
|
pubmed:volume |
296
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1633-44
|
|
pubmed:dateRevised |
2007-3-30
|
|
pubmed:meshHeading |
pubmed-meshheading:16968831-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:16968831-Cardiovascular Diseases,
pubmed-meshheading:16968831-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:16968831-Diclofenac,
pubmed-meshheading:16968831-Humans,
pubmed-meshheading:16968831-Lactones,
pubmed-meshheading:16968831-Naproxen,
pubmed-meshheading:16968831-Pyrazoles,
pubmed-meshheading:16968831-Risk,
pubmed-meshheading:16968831-Sulfonamides,
pubmed-meshheading:16968831-Sulfones
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
|
|
pubmed:affiliation |
Discipline of Clinical Pharmacology, School of Medicine and Public Health, The University of Newcastle, New South Wales, Australia.
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
